Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

Journal of Drug Targeting

Volumn 18, Issue 7, 2010, Pages 489-498

  Tamilvanan, Shunmugaperumal ^a,b,c,d   Raja, Natarajan Livingston ^a   Sa, Biswanath ^c   Basu, Sanat Kumar ^c  

^a ARULMIGU KALASALINGAM COLLEGE OF PHARMACY   (India)

^b Sankaralingam Bhuvaneswari College of Pharmacy   (India)

^c JADAVPUR UNIVERSITY   (India)

^d INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Biopharmaceuticals; Biosimilars; Clinical concerns; Immune response; Therapy

Indexed keywords

ABSEAMED; ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHEON; BIOGRASTIM; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DRUG ANTIBODY; EPOKINE; EPORON; ESPOGEN; HEXAL; HUMAN GROWTH HORMONE; HYLENEX; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGETRON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTHROMBIN COMPLEX; RATIOGRASTIM; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAGON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; REIFERON RETARD; RELIFERON; RIBAVIRIN; SALCATONIN; SB 309; TEVAGRASTIM; UNCLASSIFIED DRUG; WEPOX; BIOLOGICAL PRODUCT;

ANAPHYLAXIS; ANEMIA; ANTIBODY PRODUCTION; CELL LEVEL; CELLULAR PARAMETERS; CLINICAL TRIAL; CROSS REACTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; GROWTH HORMONE DEFICIENCY; HAIRY CELL LEUKEMIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; INJECTION SITE URTICARIA; KIDNEY CARCINOMA; LOW DRUG DOSE; MYELOID LEUKEMIA; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RENAL ANEMIA; REVIEW; SERUM SICKNESS; ANIMAL; DRUG DESIGN; IMMUNOLOGY; THERAPEUTIC EQUIVALENCE;

ANIMALS; ANTIBODY FORMATION; BIOLOGICAL PRODUCTS; DRUG DESIGN; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 77954269066     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003649746     Document Type: Review

References (96)

1. Albertsson-Wikland K. (1987). Clinical trial with authentic recom-binant somatropin in Sweden and Finland. Acta Paediatr Scand Suppl, 331, 28-34.
2. Anand S, Nissenson AR. (2003). Pure red-cell aplasia: an emerging epidemic in dialysis patients? Perit Dial Int, 23, 317-319.
3. Australian Drug Evaluation Committee.(2005). 240th Meeting Recommendations. [cited August 3, 2007]. http://www.tga. gov.au/docs/html/adec/ adec0240.htm, (last accessed January 2010).
4. Bennett CL, Cournoyer D, Carson KR, et al. (2005). Long-term outcome of individuals with pure red cell aplasia and antierythro-poietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood, 106, 3343-3347.
5. Bennett CL, Luminari S, Nissenson AR, et al. (2004). Pure red-cell aplasia and epoetin therapy. N Engl J Med, 351, 1403-1408.
6. Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B. (1990). Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood, 75, 839-845. (Pubitemid 20067180)
7. Bokemeyer C, Aapro MS, Courdi A, et al. (2007). EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer, 43, 258-270.
8. Bonetti P, Diodati G, Drago C, et al. (1994). Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol, 20, 416-420.
9. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. (2005a). Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant, 20(Suppl 3), iii33-iii40.
10. Boven K, Stryker S, Knight J, et al. (2005b). Te increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int, 67, 2346-2353.
11. Braun A, Kwee L, Labow MA, Alsenz J. (1997). Protein aggregates seem to play a key role among the parameters infuencing the anti-genicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res, 14, 1472-1478.
12. Bray GL, Gomperts ED, Courter S, et al. (1994). A multicenter study of recombinant factor VIII (recombinate): safety, efcacy, and inhibitor risk in previously untreated patients with hemophilia A. Te Recombinate Study Group. Blood, 83, 2428-2435.
13. Bruinink A. (2008). In vitro toxicokinetics and dynamics: modeling and interpretation of toxicity data. In Gad SC. (ed.), Preclinical Development Handbook: Toxicology. NJ: John Wiley & Sons, Inc., Chap. 15, pp. 509-550.
14. Casadevall N. (2002). Antibodies against rHuEPO: native and recom-binant. Nephrol Dial Transplant, 17(Suppl 5), 42-47.
15. Casadevall N, Nataf J, Viron B, et al. (2002). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recom-binant erythropoietin. N Engl J Med, 346, 469-475. (Pubitemid 34441737)
16. Combe C, Tredree RL, Schellekens H. (2005). Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharma-ceutical proteins. Pharmacotherapy, 25, 954-962.
17. Cournoyer D, Tofelmire EB, Wells GA, et al. (2004). Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol, 15, 2728-2734.
18. Covic A, Kuhlmann MK. (2007). Biosimilars: recent developments. Int Urol Nephrol, 39, 261-266.
19. Deechongkit S, Aoki KH, Park SS, Kerwin BA. (2006). Biophysical comparability of the same protein from diferent manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci, 95, 1931-1943.
20. De Groot AS, Moise L. (2007). Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Dev, 10, 332-340.
21. De Groot AS, Martin W. (2009). Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol, 131, 189-201.
22. De Groot AS, Scott DW. (2007). Immunogenicity of protein therapeutics. Trends Immunol, 28, 482-490.
23. De Groot AS, Moise L, McMurry JA, et al. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood, 112, 3303-3311.
24. Dianzani F, Antonelli G, Amicucci P, Cefaro A, Pintus C. (1989). Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients. J Interferon Res, 9(Suppl 1), S33-S36.
25. Douglas DD, Rakela J, Lin HJ, et al. (1993). Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci, 38, 601-607.
26. Dudzinski DM, Kesselheim AS. (2008). Scientifc and legal viability of follow-on protein drugs. N Engl J Med, 358, 843-849.
27. Eckardt KU, Casadevall N. (2003). Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant, 18, 865-869.
28. Ehrenforth S, Kreuz W, Scharrer I, et al. (1992). Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594-598.
29. European Medicines Agency. (2006). Omnitrope: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Omnitrope/060706en6.pdf (Last accessed on March 4, 2009).
30. European Medicines Agency. (2006a). Valtropin: EPAR summary for the public. http://www.emea.europa.eu/humandocs/PDFs/EPAR/valtropin/H-602-en1.pdf (Last accessed March 4, 2009).
31. European Medicines Agency. (2006b). Valtropin: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/valtropin/H-602-en6.pdf (Last accessed March 4, 2009).
32. European Medicines Agency. (2006). Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins. http://www.emea. europa.eu/pdfs/human/biosimilar/9452605en.pdf (Last accessed March 4, 2009).
33. European Medicines Agency. (2007). Omnitrope: EPAR summary for the public. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Omnitrope/060706en1.pdf (Last accessed March 3, 2009).
34. European Medicines Agency. (2007). Epoetin alfa HEXAL: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/epoetinalfahexal/H- 726-en6.pdf (Last accessed March 4, 2009).
35. European Medicines Agency. (2007). Binocrit: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/binocrit/H-725-en6.pdf (Last accessed March 4, 2009).
36. European Medicines Agency. (2007). Abseamed: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/abseamed/H-727-en6.pdf (Last accessed March 4, 2009).
37. European Medicines Agency. (2007). Silapo: EPAR summary for the public. http://www.emea.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-en1.pdf (Last accessed March 4, 2009).
38. European Medicines Agency. (2007). Silapo: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-en6.pdf (Last accessed March 4, 2009).
39. European Medicines Agency. (2007). Retacrit: scientifc discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/retacrit/H-872-en6.pdf (Last accessed March 4, 2009).
40. European Medicines Agency. (2008). Retacrit: EPAR summary for the public. http://www.emea.europa.eu/humandocs/PDFs/EPAR/retacrit/H-872-en1.pdf (Last accessed March 4, 2009).
41. Figlin RA, Itri LM. (1988). Anti-interferon antibodies: a perspective. Semin Hematol, 25, 9-15.
42. Freund M, von Wussow P, Diedrich H, et al. (1989). Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol, 72, 350-356.
43. Frost H. (2005). Antibody-mediated side efects of recombinant proteins. Toxicology, 209, 155-160.
44. Gottlieb S. (2008). Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm, 65, S2-S8.
45. Hoyer LW. (1993). Factor VIII inhibitors: a continuing problem. J Lab Clin Med, 121, 385-387.
46. Hoyer LW. (1995). Factor VIII inhibitors. Curr Opin Hematol, 2, 365-371.
47. Hynes DM, Stroupe KT, Greer JW, et al. (2002). Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med, 112, 169-175.
48. Important Drug Safety Update EPREX. (2002). (Epoetin alfa)-pure red cell aplasia (PRCA, Erythroblastopenia). Health Canada. [cited August 22, 2007]. http://www.hc-sc.gc.ca/dhp-mps/alt-for-mats/hpfbdgpsa/pdf/medef/ eprex-2-hpc-cps-e.pdf. 2007 (Last accessed December 4, 2009).
49. Jones GJ, Itri LM. (1986). Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer, 57, 1709-1715.
50. Kaplan SL, Underwood LE, August GP, et al. (1986). Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone defcient children. Lancet, 1, 697-700.
51. Kaufman JS. (1998). Subcutaneous erythropoietin therapy: efcacy and economic implications. Am J Kidney Dis, 32, S147-S151.
52. Keithi-Reddy SR, Kandasamy S, Singh AK. (2008). Pure red cell aplasia due to follow-on epoetin. Kidney Int, 74, 1617-1622.
53. Krämer I. (2008). Pharmacy and pharmacology of biosimilars. J Endocrinol Invest, 31, 479-488.
54. Kresse GB. (2009). Biosimilars-science, status, and strategic perspective. Eur J Pharm Biopharm, 72, 479-486.
55. Kromminga A, Schellekens H. (2005). Antibodies against erythropoi-etin and other protein-based therapeutics: an overview. Ann N Y Acad Sci, 1050, 257-265.
56. Lacroix-Desmazes S, Bayry J, Misra N, et al. (2002). Te prevalence of proteolytic antibodies against factor VIII in Haemophilia A. N Engl J Med, 346, 662-667. (Pubitemid 34815870)
57. Locatelli F, Aljama P, Bárány P, et al. (2004). Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19(Suppl 2), ii1-ii47.
58. Lok AS, Lai CL, Leung EK. (1990). Interferon antibodies may negate the antiviral efects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology, 12, 1266-1270.
59. Lundin K, Berger L, Blomberg F, Wilton P. (1991). Development of anti-hGH antibodies during therapy with authentic human growth hormone. Acta Paediatr Scand Suppl, 372, 167-168.
60. Lusher JM. (2000). Inhibitor antibodies to factor VIII and factor IX: management. Semin Tromb Hemost, 26, 179-188.
61. Lusher JM, Arkin S, Abildgaard C F, Schwartz RS. (1993). Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efcacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med, 328, 453-459.
62. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. (1993). Five-year follow-up of growth hormone antibodies in growth hormone defcient children treated with recombinant human growth hormone. Clin Endocrinol (Oxf), 38, 137-142.
63. McKoy JM, Stonecash RE, Cournoyer D, et al. (2008). Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion, 48, 1754-1762.
64. Mellstedt H, Niederwieser D, Ludwig H. (2008). Te challenge of biosimilars. Ann Oncol, 19, 411-419.
65. German Medical Association. (January 2009). Newsletter 2008-2130 Newsletter@akdae.de.
66. Okada Y, Taira K, Takano K, Hizuka N. (1987). A case report of growth attenuation during methionyl human growth hormone treatment. Endocrinol Jpn, 34, 621-626. (Pubitemid 19001414)
67. Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. (2004). Environmental and genetic factors infu-encing inhibitor development. Semin Hematol, 41, 82-88.
68. Opdenakker G, Van den Steen PE, Laureys G, Hunninck K, Arnold B. (2003). Neutralizing antibodies in gene-defective hosts. Trends Immunol, 24, 94-100.
69. Park S, Patel K, Ko J, et al. (2006). Analytical comparisons of erythro-poietin products from Korea and Amgen's Epogen® (epoetin alfa) [abstract]. Nephrol Dial Transplant, 21, iv14.
70. Porter S. (2001). Human immune response to recombinant human proteins. J Pharm Sci, 90, 1-11.
71. PRCA Update. (2007). [cited June 1, 2007]. http://www.amgen.com/patients/ prca.html (Last accessed December 4, 2009).
72. Richard Tacey R, Greway A, Smiell J, Power D, Kromminga A, Daha M, Casadevall N, Kelley M. (2003). Te detection of anti-erythropoi-etin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods, 283:317-329
73. Romer T, Peter F, Saenger P, et al. (2007). Efcacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest, 30, 578-589.
74. Rosenberg RS. (2006). Efects of protein aggregates: an immunologic perspective. AAPS J, 8, E501-E507.
75. Sasaki H, Bothner B, Dell A, Fukuda M. (1987). Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem, 262, 12059-12076.
76. Schellekens H. (2004). Biosimilar epoetins: how similar are they? Eur J Hosp Pharm Sci, 3, 43-47.
77. Schellekens H. (2005). Factors infuencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant, 20(Suppl 6), vi3-vi9.
78. Schellekens H. (2008a). Recombinant human erythropoietins, biosim-ilars and immunogenicity. J Nephrol, 21, 497-502.
79. Schellekens H. (2008b). Te frst biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol, 3, 174-178.
80. Schellekens H. (2009). Biosimilar therapeutics-what do we need to consider? NDT Plus, 2, i27-i36.
81. Schellekens H, Casadevall N. (2004). Immunogenicity of recombinant human proteins: causes and consequences. J Neurol, 251(Suppl 2), II4-II9.
82. Schellekens H, Jiskoot W. (2006). Eprex-associated pure red cell apla-sia and leachates. Nat Biotechnol, 24, 613-614.
83. Schneider CK, Kalinke U. (2008). Toward biosimilar monoclonal antibodies. Nat Biotechnol, 26, 985-990.
84. Shacter E. (2000). Quantifcation and signifcance of protein oxidation in biological samples. Drug Metab Rev, 32, 307-326.
85. Skibeli V, Nissen-Lie G, Torjesen P. (2001). Sugar profling proves that human serum erythropoietin difers from recombinant human erythropoietin. Blood, 98, 3626-3634.
86. Steis RG, Smith JW II, Urba WJ, et al. (1988). Resistance to recom-binant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med, 318, 1409-1413.
87. Stravitz RT, Chung H, Sterling RK, et al. (2005). Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol, 100, 1415-1419.
88. Summary of PRCA Case Reports.(2008). Update on our company's efort to reduce case reports of pure red cell aplasia. [cited February 11, 2008]. http://www.jnjpharmarnd.com/jnjpharmarnd/
89. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. (2004). Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract, 96, c88-c95.
90. Taguchi N, Ito S. (2005). Paternal use of ribavirin-interferon alpha 2B combination therapy before conception. Can Fam Physician, 51, 1623-1625.
91. Takano K, Shizume K, Hibi I. (1989). Turner's syndrome: treatment of 203 patients with recombinant human growth hormone for one year. A multicentre study. Acta Endocrinol, 120, 559-568.
92. Tangri S, Mothé BR, Eisenbraun J, et al. (2005). Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol, 174, 3187-3196.
93. Wang W. (2005). Protein aggregation and its inhibition in biopharma-ceutics. Int J Pharm, 289, 1-30.
94. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. (2002). Allergic skin and systemic reactions in a patient with pure red cell apla-sia and anti-erythropoietin antibodies challenged with diferent epoetins. J Am Soc Nephrol, 13, 2381-2383.
95. Wilton P, Gunnarsson R. (1988). Clinical experience with Genotropin in growth hormone defcient children. Acta Paediatr Scand Suppl, 343, 95-101.
96. Woodburn KW, Fan Q, Winslow S, et al. (2007). Hematide is immu-nologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol, 35, 1201-1208.